MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtronic Joins U.S. DES Market

Medtronic on Friday received FDA approval for its entry into the embattled but still lucrative drug-eluting stent market, Endeavor. It is the third product of its kind to be cleared for marketing in the United States, and the first since the controversy over the products' potential to cause blood clots led to greater safety scrutiny.

CDRH Director Daniel Schultz said approval was granted after the center reviewed "a substantial amount of clinical evidence." Nothing less would have flown in today's climate. Indeed, Medtronic showed the agency data from a whopping seven trials. Their findings included positive data on the device's performance in regards to heart attack, cardiac death, and repeat procedures to re-open the coronary artery. Also importantly, blood-clot risk was similar to that for bare-metal stents. However, the agency advises patients to take blood-thinning medication for at least six months after the procedure. Also good news for Medtronic is that the DES market appears to have bottomed out. The Wall Street Journal reports that the market share for drug-eluting stents is no longer falling. It held steady for all four quarters of 2007.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish